U.S. justices reject Johnson & Johnson unit's anti-psychotic drug appeal

January 11, 2016 3:05 PM

33 0

WASHINGTON The U.S. Supreme Court on Monday declined to hear a Johnson & Johnson subsidiary's appeal of a $124 million penalty imposed by South Carolina after a jury found the drugmaker had improperly marketed the anti-psychotic drug Risperdal and concealed its risks.

The court's decision not to hear the appeal filed by Johnson & Johnson's Janssen Pharmaceuticals means a South Carolina Supreme Court ruling from June that reduced the penalty to $124 million from $327 million remains intact.

Also read: Conviction of SAC's Martoma upheld despite jury instructions

Read more

To category page